GU Cancers 2024 | Assessing the role of perioperative immunotherapy in MIBC

Andrea Apolo, MD, National Institutes of Health, Bethesda, MD, comments on the emerging role of adjuvant and neoadjuvant immunotherapy in muscle-invasive bladder cancer (MIBC). Findings from the Phase III AMBASSADOR trial (NCT03244384) have recently demonstrated the utility of adjuvant checkpoint inhibition in high-risk metastatic MIBC and Dr Apolo additionally highlights the sandwich approach, where neoadjuvant and adjuvant treatment is both given before and after surgery. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.